Last 12 months
Inside the activity.
7 purchase rows · 25 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 9 |
| Jan 2026 | 0 | 7 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 2 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 2 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 20, 2026 Filed Jan 22, 2026 00:17 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 2,000 | $0.06 | $120.00 |
DisclosureSEC source: 0001301120-26-000006 · wk-form4_1769041031.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 14, 2026 Filed Jan 14, 2026 17:56 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,084 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-26-000004 · wk-form4_1768413405.xml · derivative · entry 6 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 332,686 Underlying: Common Stock · 1,084 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| January 14, 2026 Filed Jan 14, 2026 17:56 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 1,084 | $2.50 | $2,713.36 |
DisclosureSEC source: 0001301120-26-000004 · wk-form4_1768413405.xml · nonDerivative · entry 4 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.54 to $2.50. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| January 14, 2026 Filed Jan 14, 2026 17:56 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 1,084 | $0.06 | $65.04 |
DisclosureSEC source: 0001301120-26-000004 · wk-form4_1768413405.xml · nonDerivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,084 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 13, 2026 Filed Jan 14, 2026 17:56 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,416 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-26-000004 · wk-form4_1768413405.xml · derivative · entry 5 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 333,770 Underlying: Common Stock · 5,416 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| January 13, 2026 Filed Jan 14, 2026 17:56 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 5,416 | $2.50 | $13,540.00 |
DisclosureSEC source: 0001301120-26-000004 · wk-form4_1768413405.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 13, 2026 Filed Jan 14, 2026 17:56 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 5,416 | $0.06 | $324.96 |
DisclosureSEC source: 0001301120-26-000004 · wk-form4_1768413405.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2026 Filed Jan 9, 2026 17:27 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 13,000 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-26-000002 · wk-form4_1767979647.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 339,186 Underlying: Common Stock · 13,000 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| January 08, 2026 Filed Jan 9, 2026 17:27 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 13,000 | $2.69 | $34,953.10 |
DisclosureSEC source: 0001301120-26-000002 · wk-form4_1767979647.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.85 to $2.60. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F1 · balance_after: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.85 to $2.60. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| January 08, 2026 Filed Jan 9, 2026 17:27 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 13,000 | $0.06 | $780.00 |
DisclosureSEC source: 0001301120-26-000002 · wk-form4_1767979647.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 16:40 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,100 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000039 · wk-form4_1767026407.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 352,186 Underlying: Common Stock · 4,100 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 16:40 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 4,100 | $2.60 | $10,660.00 |
DisclosureSEC source: 0001301120-25-000039 · wk-form4_1767026407.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 16:40 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 4,100 | $0.06 | $246.00 |
DisclosureSEC source: 0001301120-25-000039 · wk-form4_1767026407.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 19:04 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,673 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000037 · wk-form4_1766516671.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 356,286 Underlying: Common Stock · 5,673 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 19:04 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 5,673 | $2.67 | $15,167.90 |
DisclosureSEC source: 0001301120-25-000037 · wk-form4_1766516671.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.705 to $2.66. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 19:04 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 5,673 | $0.06 | $340.38 |
DisclosureSEC source: 0001301120-25-000037 · wk-form4_1766516671.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 00:56 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 3,227 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000035 · wk-form4_1766019414.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 361,959 Underlying: Common Stock · 3,227 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 00:56 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 3,227 | $2.96 | $9,561.92 |
DisclosureSEC source: 0001301120-25-000035 · wk-form4_1766019414.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.00 to $2.96. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 00:56 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 3,227 | $0.06 | $193.62 |
DisclosureSEC source: 0001301120-25-000035 · wk-form4_1766019414.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,227 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 23:59 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,700 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000033 · wk-form4_1765929561.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 365,186 Underlying: Common Stock · 1,700 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 23:59 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 1,700 | $3.26 | $5,541.49 |
DisclosureSEC source: 0001301120-25-000033 · wk-form4_1765929561.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.25 to $3.275. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 23:59 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 1,700 | $0.06 | $102.00 |
DisclosureSEC source: 0001301120-25-000033 · wk-form4_1765929561.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2025 Filed Dec 12, 2025 17:48 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 3,555 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000030 · wk-form4_1765561686.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 366,886 Underlying: Common Stock · 3,555 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| December 11, 2025 Filed Dec 12, 2025 17:48 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 3,555 | $3.24 | $11,519.62 |
DisclosureSEC source: 0001301120-25-000030 · wk-form4_1765561686.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.20 to $3.35. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| December 11, 2025 Filed Dec 12, 2025 17:48 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 3,555 | $0.06 | $213.30 |
DisclosureSEC source: 0001301120-25-000030 · wk-form4_1765561686.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2025 Filed Dec 11, 2025 21:11 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 645 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000027 · wk-form4_1765487480.xml · derivative · entry 6 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 370,441 Underlying: Common Stock · 645 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| December 10, 2025 Filed Dec 11, 2025 21:11 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 645 | $3.35 | $2,160.75 |
DisclosureSEC source: 0001301120-25-000027 · wk-form4_1765487480.xml · nonDerivative · entry 4 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Read SEC document |
| December 10, 2025 Filed Dec 11, 2025 21:11 UTC |
Moreadith RandallChief Scientific Officer
|
GrantCommon Stock | 645 | $0.06 | $38.70 |
DisclosureSEC source: 0001301120-25-000027 · wk-form4_1765487480.xml · nonDerivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 645 Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:11 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 600 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000027 · wk-form4_1765487480.xml · derivative · entry 5 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 371,086 Underlying: Common Stock · 600 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:11 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 600 | $3.31 | $1,987.98 |
DisclosureSEC source: 0001301120-25-000027 · wk-form4_1765487480.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.31 to $3.315. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:11 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 600 | $0.06 | $36.00 |
DisclosureSEC source: 0001301120-25-000027 · wk-form4_1765487480.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 00:56 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000025 · wk-form4_1764896157.xml · derivative · entry 6 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 371,686 Underlying: Common Stock · 5,000 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 00:56 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 5,000 | $3.52 | $17,623.00 |
DisclosureSEC source: 0001301120-25-000025 · wk-form4_1764896157.xml · nonDerivative · entry 4 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F2 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.47 to $3.55. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · balance_after: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.47 to $3.55. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 00:56 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 5,000 | $0.06 | $300.00 |
DisclosureSEC source: 0001301120-25-000025 · wk-form4_1764896157.xml · nonDerivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 00:56 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000025 · wk-form4_1764896157.xml · derivative · entry 5 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 376,686 Underlying: Common Stock · 1,500 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 00:56 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 1,500 | $3.91 | $5,857.80 |
DisclosureSEC source: 0001301120-25-000025 · wk-form4_1764896157.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.90 to $3.9112. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 00:56 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 1,500 | $0.06 | $90.00 |
DisclosureSEC source: 0001301120-25-000025 · wk-form4_1764896157.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:21 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,965 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000023 · wk-form4_1764195711.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 378,186 Underlying: Common Stock · 5,965 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:21 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 5,965 | $3.90 | $23,264.10 |
DisclosureSEC source: 0001301120-25-000023 · wk-form4_1764195711.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,965 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.90 to $3.91. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:21 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 5,965 | $0.06 | $357.90 |
DisclosureSEC source: 0001301120-25-000023 · wk-form4_1764195711.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,930 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 02:20 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 535 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001628280-25-054059 · wk-form4_1764123603.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 384,151 Underlying: Common Stock · 535 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 02:20 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 535 | $3.94 | $2,105.23 |
DisclosureSEC source: 0001628280-25-054059 · wk-form4_1764123603.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.98 to $3.917. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 02:20 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 535 | $0.06 | $32.10 |
DisclosureSEC source: 0001628280-25-054059 · wk-form4_1764123603.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2025 Filed Nov 19, 2025 18:47 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000021 · wk-form4_1763578063.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 384,686 Underlying: Common Stock · 6,500 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| November 18, 2025 Filed Nov 19, 2025 18:47 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 6,500 | $3.75 | $24,401.65 |
DisclosureSEC source: 0001301120-25-000021 · wk-form4_1763578063.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.90 to $3.71. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| November 18, 2025 Filed Nov 19, 2025 18:47 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 6,500 | $0.06 | $390.00 |
DisclosureSEC source: 0001301120-25-000021 · wk-form4_1763578063.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 17:38 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000019 · wk-form4_1762969093.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 391,186 Underlying: Common Stock · 6,500 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 17:38 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 6,500 | $4.10 | $26,650.00 |
DisclosureSEC source: 0001301120-25-000019 · wk-form4_1762969093.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.30 to $4.00. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 17:38 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 6,500 | $0.06 | $390.00 |
DisclosureSEC source: 0001301120-25-000019 · wk-form4_1762969093.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2025 Filed Nov 11, 2025 01:02 UTC |
Marshall Richard PeterDirector
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0002016188-25-000003 · wk-form4_1762822939.xml · derivative · entry 1 Marshall Richard Peter · CIK 0002016188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-11-07 F1 · derivative.exercise_date: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.